Actions of S18327 in models predictive of extrapyramidal side effects
| Induction of catalepsy | Inhibition of methylphenidate gnawing | Induction of PRL secretion | ||||
|---|---|---|---|---|---|---|
| AD50(95% CL) | %MOE (dose) | ID50 (95% CL) | %MOE (dose) | MED | MOE (dose) | |
| S18327 | 22.2 (10.4–47.5) | 55 (40.0) | >40.0 | 0 (40.0) | 2.5 | 20.4 ± 5.2 (2.5) |
AD50 (95% CL), active dose50 (95% confidence limits); ID50, inhibitory dose50; %MOE, %maximal observed effect (dose at which obtained); MED, minimal effective dose. For catalepsy, %MOE is relative to a limit of 30 s. For PRL secretion, MOE is expressed in ng/ml relative to basal, levels of 4.3 ± 1.1 ng/ml. Doses are in mg/kg, s.c.